Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.17
(-4.69%)
SEK 0.17
(-4.69%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 16.4 Million SEK | 4106.92% |
| 2022 | 390 Thousand SEK | -87.74% |
| 2021 | 3.18 Million SEK | -25.67% |
| 2020 | 4.27 Million SEK | 145.44% |
| 2019 | 1.74 Million SEK | 9583.33% |
| 2018 | 18 Thousand SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 8.97 Million SEK | 0.0% |
| 2024 Q1 | - SEK | 0.0% |
| 2023 FY | 16.4 Million SEK | 4106.92% |
| 2023 Q2 | 16.05 Million SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q4 | - SEK | -100.0% |
| 2023 Q3 | 357 Thousand SEK | -97.78% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q4 | 390 Thousand SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q1 | - SEK | -100.0% |
| 2022 FY | 390 Thousand SEK | -87.74% |
| 2021 FY | 3.18 Million SEK | -25.67% |
| 2021 Q2 | 768 Thousand SEK | -35.95% |
| 2021 Q4 | 463 Thousand SEK | -38.18% |
| 2021 Q1 | 1.19 Million SEK | 46.04% |
| 2021 Q3 | 749 Thousand SEK | -2.47% |
| 2020 Q1 | 707 Thousand SEK | 0.0% |
| 2020 FY | 4.27 Million SEK | 145.44% |
| 2020 Q4 | 821 Thousand SEK | -61.71% |
| 2020 Q3 | 2.14 Million SEK | 253.8% |
| 2020 Q2 | 606 Thousand SEK | -14.29% |
| 2019 FY | 1.74 Million SEK | 9583.33% |
| 2018 FY | 18 Thousand SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 71.764% |
| Ziccum AB (publ) | 3.74 Million SEK | -337.87% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 97.337% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 67.501% |
| Mendus AB (publ) | 28.48 Million SEK | 42.405% |
| Genovis AB (publ.) | 158.23 Million SEK | 89.631% |
| Intervacc AB (publ) | 8.01 Million SEK | -104.704% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -275.103% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 90.374% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 62.623% |
| Aptahem AB (publ) | 2.63 Million SEK | -523.687% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -1485.217% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -21207.792% |
| Fluicell AB (publ) | 3.33 Million SEK | -391.522% |
| Saniona AB (publ) | 16.84 Million SEK | 2.571% |
| Biovica International AB (publ) | 7.29 Million SEK | -125.062% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -1263.84% |
| AcouSort AB (publ) | 10.55 Million SEK | -55.502% |
| Xintela AB (publ) | 78 Thousand SEK | -20934.615% |
| Abliva AB (publ) | 137 Thousand SEK | -11875.912% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 71.516% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -714.647% |
| OncoZenge AB (publ) | 3000.00 SEK | -546800.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -10485.161% |
| CombiGene AB (publ) | 5.54 Million SEK | -195.935% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 98.641% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.044% |
| Corline Biomedical AB | 25.03 Million SEK | 34.451% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -188.957% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -2175.589% |
| I-Tech AB | 120.86 Million SEK | 86.425% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 87.765% |
| Cyxone AB (publ) | 5.14 Million SEK | -218.706% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -132.723% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -53.844% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -46.099% |
| Nanologica AB (publ) | 1.44 Million SEK | -1037.006% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -30856.604% |
| BioInvent International AB (publ) | 71.46 Million SEK | 77.041% |
| Alzinova AB (publ) | 270 Thousand SEK | -5976.667% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 53.416% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1021.447% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -481.396% |
| Simris Alg AB (publ) | 4.35 Million SEK | -276.826% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -12520.769% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 93.127% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -71234.783% |